April 30th 2025
The company’s intent is to establish Merck Wilmington Biotech as the future United States home for producing Keytruda for US patients.
The evolution of therapeutic modalities drives the adoption of single-use technologies.
Single-Use Bioreactors for the Rapid Production of Preclinical and Clinical Biopharmaceuticals
Fed-batch processes were scaled up from traditional bench-scale bioreactors to large-scale single-use systems.